Novartis's Andrew Topen appointed as new chairman of EuropaBio

Press Release

3 September 2020, Brussels: Today, EuropaBio’s General Assembly confirmed the appointment of Andrew Topen as the new Chairman of the association. Andrew Topen joined Novartis in September 2019 and has since then lead the overall public affairs strategy and strategic relationships within Region Europe.

Commenting on his appointment, Andrew Topen highlighted: ‘I am proud to take over the chairmanship of EuropaBio at a time when biotechnology is so critical to tackle society’s greatest challenges. EuropaBio holds a unique position to promote biotechnology innovations to the benefit of people and the planet. EuropaBio has an important role to play in shaping the European Green Deal and the Farm to Fork, the Industrial, Pharmaceutical and Digital strategies to set the course towards Europe’s economic recovery and the fight against climate change. Life sciences and biotechnology are making a healthier, more resilient, and sustainable Europe possible, one that is able to swiftly recover from the current crisis and delivers for its citizens, its regions, and its economy. I would like to thank Tjerk de Ruiter for his leadership of EuropaBio over the last two years and the EuropaBio team for their ongoing efforts to advance biotechnology in Europe.’

ENDS

Media contact

Kai Künnecke, EuropaBio Communications Officer
Email: k.kuennecke@europabio.org / Telephone: +32 2 739 11 81

About EuropaBio

EuropaBio, the European Association for Bioindustries, promotes an innovative and dynamic European biotechnology industry. EuropaBio and its members are committed to the socially responsible use of biotechnology to improve quality of life, to prevent, diagnose, treat and cure diseases, to improve the quality and quantity of food and feedstuffs and to move towards a biobased and zero-waste economy. EuropaBio represents 75 corporate members and 17 national biotechnology associations and bioregions.

Read more about our work at www.europabio.org.